These findings suggest that PIK3CA, KRAS or BRAF mutations may contribute to MEK or PI3K inhibitor resistance and that a combination of Akt and MEK inhibitors may be a useful pharmacotherapeutic approach for colorectal cancer harboring dual mutations of PIK3CA and KRAS or BRAF. This evidence concerns the gene PIK3CA and colorectal cancer.